Stay updated with breaking news from Beckley Psytech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
5-MeO-DMT used for depression for those who do not respond to traditional and first-line therapeutics; results show a rapid antidepressant response in 55% of patients.
A phase 2a open-label study found BL-003 for treatment-resistant depression was well-tolerated and any acute effects resolved on average in less than 2 hours.
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003 ...
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment...